Hemostatic Effects of Tamoxifen in Hereditary Hemorrhagic Telangiectasia

Leo R. Zacharski; Scott D. Dunbar; William A. Newsom Jr.

doi:10.1055/s-0037-1615709

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2001; 85(02): 371-372
DOI: 10.1055/s-0037-1615709

Letters to the Editor

Schattauer GmbH

Hemostatic Effects of Tamoxifen in Hereditary Hemorrhagic Telangiectasia

Authors

Leo R. Zacharski

¹Department of Veterans Affairs Medical Center, White River Jct., Vermont
Scott D. Dunbar

²Department of Medicine, Dartmouth Medical School, Lebanon, NH
William A. Newsom Jr.

³Sierra Nevada Cancer Center, Grass Valley, California, USA

Abstract

Full Text

References

References
1 Jacobson BS. Hereditary hemorrhagic telangiectasia: A model for blood vessel growth and enlargement. Am J Pathol 2000; 156: 737-42.
2 Lund VJ, Howard DJ. A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia. Am J Rhinol 1999; 13: 319-22.
3 Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999; 25: 137-45.
4 Oberhoff C, Szymeczek J, Hoffmann O, Winkler UH, Kaiser S, Schindler AE. Adjuvant antiestrogen treatment with tamoxifen in postmenopausal women with breast cancer: a longitudinal study of blood coagulation and fibrinolysis. Breast Cancer Res Treat 1998; 50: 73-81.
5 Ounnoughene N, Molho P, Stieltjes N, Sultan Y. Effect of tamoxifen on von Willebrand factor levels. Arch Intern Med 1977; 157: 1613.
6 Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med 1996; 156: 1806-10.
7 Pemberton KD, Melissari E, Kakkar VV. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis. 1993; 4: 935-42.
8 Japan Advanced Breast Cancer Study Group and Japan Clinical Oncology Group.. Effects of chemoendocrine therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer. Jpn J. Cancer Res 1993; 84: 455-61.
9 Fukutomi T, Adachi I, Watanabe T, Nanasawa T, Yamamoto H. Effects of combined tamoxifen and medroxyprogesterone treatment on coagulationfibrinolytic systems in patients with advanced breast cancer. Acta Oncol 1993; 32: 573-4.
10 Jankowski J, Ramlau C, Kopczynski Z, Boryska M. The influence of tamoxifen on plasma coagulation and serous fibrinolysis. Eur J. Gynaecol Oncol 1993; 14: 155-8.
11 Caleffi M, Fentiman IS, Clark GM, Wang DY, Needham J, Clark K, La Ville A, Lewis B. Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain. J Endocrinol 1988; 119: 335-9.
12 Auger MJ, Mackie MJ. Effects of tamoxifen on blood coagulation. Cancer 1988; 61: 1316-9.
13 Sureda A, Cesar J, Garcia Frade LJ, Garcia Avello A, Fernandez Fuertes I, Navarro JL. Hereditary hemorrhagic telangiectasia: analysis of platelet aggregation and fibrinolytic system in seven patients. Acta Haematol 1991; 85: 119-23.
14 Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer 1997; 79: 2024-7.
15 Grann VR, Sundararajan V, Jacobson JS, Whang W, Heitjan DF, Antman KH, Neugut AI. Decision Analysis Of Tamoxifen for the Prevention of Invasive Breast Cancer. Cancer J 2000; 6: 169-178.
16 Dunbar S.D., Ornstein D. L., Zacharski L.R.. Treatment of cancer with inhibitors of the plasminogen activator – plasmin system. Exp Opin Invest Drugs 2000; 9: 2085-92.
17 Xing RH, Mazar A, Henkin J, Rabbani SA. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res 1997; 57: 3585-93.
18 Kwaan HC, Silverman S. Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia. Arch Dermatol 1973; 107 (Suppl. 04) 571-3.
19 Richtsmeier W, Weaver G, Streck W, Jacobson H, Dewell R, Olson J. Estrogen and progesterone receptors in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 1984; 92: 564-70.
20 Santibanez JF, Iglesias M, Frontelo P, Martinez J, Quintanilla M. Involvement of the Ras/MAPK Signaling Pathway in the Modulation of Urokinase Production and Cellular Invasiveness by Transforming Growth Factor-beta(1) in Transformed Keratinocytes. Biochem Biophys Res Commun 2000; 273: 521-7.
21 Park IK, Lyu MA, Yeo SJ, Han TH, Kook YH. Sp1 mediates constitutive and transforming growth factor beta-inducible expression of urokinase type plasminogen activator receptor gene in human monocyte-like U937 cells. Biochim Biophys Acta 2000; 1490 (Suppl. 03) 302-10.
22 Letamendia A, Lastres P, Botella LM, Raab U, Langa C, Velasco B, Attisano L, Bernabeu C. Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem 1998; 273: 33011-9.
23 Wileman SM, Booth NA, Moore N, Redmill B, Forrester JV, Knott RM. Regulation of plasminogen activation by TGF-beta in culutred human retinal endothelial cells. Br J Ophthalmol 2000; 84: 417-22.
24 Kim H, Peterson TG, Barnes S. Mechanisms of action of the soy isoflavone genestein: emerging role for its effects via transforming growth factor beta signalling pathways. Am J Clin Nutr 1998; 68: 1418S-25S.
25 Takahashi H, Uno S, Watanabe Y, Arakawa K, Nakagawa S. Expression of nerve growth factor-induced type 1 plasminogen activator inhibitor (PAI-1) mRNA is inhibited by genistein and wortmannin. Neuroreport 2000; 11 (Suppl. 05) 1111-5.
26 Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29 (Suppl. 03) 236-61.